1009-4571
2012 Issue 6
Correlation of β1 gene-509C/T polymorphism and genetic susceptibility to NSCLC in Chinese population
LI Ting1;REN Jing-hua1;MA Yan-qing1;LEI Yan-rong1;NONG Li1;ZHANG Yun2 1.Cancer Center;Union Hospital;Tongji Medical College;Huazhong University of Science and Technology; Wuhan 430023;P.R.China 2.Department of Critical Care Medicine;Yuncheng Central Hospital;Yuncheng 044000;P.R.China
LI Ting1;REN Jing-hua1;MA Yan-qing1;LEI Yan-rong1;NONG Li1;ZHANG Yun2 1.Cancer Center;Union Hospital;Tongji Medical College;Huazhong University of Science and Technology; Wuhan 430023;P.R.China 2.Department of Critical Care Medicine;Yuncheng Central Hospital;Yuncheng 044000;P.R.China
..............page:410-414
Prevention effect of EGCG in rat’s lung cancer induced by benzopyrene
FENG Qi-xiao;HUANG Jun-xian;WEI Shu-li Department of Oncology;Affiliated Chenxinghai Hospital of Guangdong Medical College;Zhongshan 528415;P.R.China
FENG Qi-xiao;HUANG Jun-xian;WEI Shu-li Department of Oncology;Affiliated Chenxinghai Hospital of Guangdong Medical College;Zhongshan 528415;P.R.China
..............page:415-418
Experimental study of damage on rats lung tissues by Gemcitabine
WANG Wei-min1;PAN Yan1;LI Bing2 1.Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University;Shanghai 200030;P.R.China 2.Department of Pneumology;Changzheng Hospital Affiliated to Second Military Medical University;Shanghai 200003;P.R.China
WANG Wei-min1;PAN Yan1;LI Bing2 1.Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University;Shanghai 200030;P.R.China 2.Department of Pneumology;Changzheng Hospital Affiliated to Second Military Medical University;Shanghai 200003;P.R.China
..............page:436-439
Meta-analysis of compare triplet regimen based on Gemcitabine with doublet regimen for advanced NSCLC
REN Yang-wu1;WANG Ding2;LI Kun1;WAN Yan1;ZHOU Bao-sen1 1.Department of Epidemiology;School of Public Health;China Medical University;Evidence-Based Medicine Center;Key Laboratory of Tumor Pathogery and Prevention of Liaoning;Shenyang 110001;P.R.China 2.Grade 95;Medical Department;China Medical University;Shenyang 110001;P.R;China
REN Yang-wu1;WANG Ding2;LI Kun1;WAN Yan1;ZHOU Bao-sen1 1.Department of Epidemiology;School of Public Health;China Medical University;Evidence-Based Medicine Center;Key Laboratory of Tumor Pathogery and Prevention of Liaoning;Shenyang 110001;P.R.China 2.Grade 95;Medical Department;China Medical University;Shenyang 110001;P.R;China
..............page:457-460
Pemetrexed combined with cispatin as the first line therapy in advanced lung adenocarcinoma
WANG Hong-yan;XU Hong-yan;HOU Wen-juan Department of Oncology;Weihai Munipal Hospital;Weihai 264200;P.R.China
WANG Hong-yan;XU Hong-yan;HOU Wen-juan Department of Oncology;Weihai Munipal Hospital;Weihai 264200;P.R.China
..............page:465-466
Research progress on the relationship between ANGPT-TIE signal system and development of tumor
GUO Fei-fei;ZHOU Huai-jun Department of Gynecology and Obstetrics;Affiliated Nanjing Drum Tower Hospital of Nanjing University; Nanjing 210008;P.R.China
GUO Fei-fei;ZHOU Huai-jun Department of Gynecology and Obstetrics;Affiliated Nanjing Drum Tower Hospital of Nanjing University; Nanjing 210008;P.R.China
..............page:471-474
..............page:396
..............page:481-482
Clinical study of ventriculo-peritoneal shunt surgery plus chemotherapy pump placement in high intracranial pressure caused by meningitis metastasis
ZHOU Shi-zhen;ZHU Yu-fang;XU Jun;YUE Xiao;WANG Yong;WANG Xiu-hua;ZHAO Yu-e;TAO Rong-jie Department of Neurosurgery;Shangdong Tumor Hospital;jinan 250117;P.R.China
ZHOU Shi-zhen;ZHU Yu-fang;XU Jun;YUE Xiao;WANG Yong;WANG Xiu-hua;ZHAO Yu-e;TAO Rong-jie Department of Neurosurgery;Shangdong Tumor Hospital;jinan 250117;P.R.China
..............page:443-445
Clinical observation of pemetrexed or palitaxel combined with concurrent radiotherapy in elderly patients with locally advanced lung adenocarcinoma
LU Yi-yu1;YANG Wen2;TANG Wu-bing2;WU Chu-rong2;PAN Xing-xi2;ZHANG Yong-sheng2 1.Department of Radiotherapy;Nanfang Medical University Nanfang Hospital;Guangzhou 510515;P.R.China 2.Department of Oncology;Nanhai Affiliated Hospital of Nanfang Medical University;Foshan 528200;P.R.China
LU Yi-yu1;YANG Wen2;TANG Wu-bing2;WU Chu-rong2;PAN Xing-xi2;ZHANG Yong-sheng2 1.Department of Radiotherapy;Nanfang Medical University Nanfang Hospital;Guangzhou 510515;P.R.China 2.Department of Oncology;Nanhai Affiliated Hospital of Nanfang Medical University;Foshan 528200;P.R.China
..............page:450-452
Sensitivity of gefitinib to human non-small cell lung cancer cell H1650 induced by 5-aza-CdR
LI Xiao-you;WU Jian-zhong;CAO Hai-xia;WU Jian-qiu;FENG Ji-feng Affiliated Cancer Hospital of Nanjing Medical University;Nanjing 210009;P.R.China
LI Xiao-you;WU Jian-zhong;CAO Hai-xia;WU Jian-qiu;FENG Ji-feng Affiliated Cancer Hospital of Nanjing Medical University;Nanjing 210009;P.R.China
..............page:423-427
Analysis of clinical and dosimetric factors associated with radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy
YANG Yang;YAN Jing;LIU Juan;REN Wei;KONG Wei-wei;GAO Shan-bao;YIN Hai-tao; QIAN Xiao-ping;LIU Bao-rui Comprehensive Cancer Center of Drum Tower Hospital;Medical School of Nanjing University;Clinical Cancer Institute of Nanjing University;Nanjing 210008;P.R.China
YANG Yang;YAN Jing;LIU Juan;REN Wei;KONG Wei-wei;GAO Shan-bao;YIN Hai-tao; QIAN Xiao-ping;LIU Bao-rui Comprehensive Cancer Center of Drum Tower Hospital;Medical School of Nanjing University;Clinical Cancer Institute of Nanjing University;Nanjing 210008;P.R.China
..............page:446-449
Mechanisms of PTEN down-regulation in lung cancer cells
SHI Jing;GAO Feng-hou;GUO Yue-hui;YUAN Hai-hua;JIANG Bin Department of Oncology;NO.3 People’s Hospital Affiliated to Medical College of Shanghai Jiaotong University;Shanghai 201900;P.R.China
SHI Jing;GAO Feng-hou;GUO Yue-hui;YUAN Hai-hua;JIANG Bin Department of Oncology;NO.3 People’s Hospital Affiliated to Medical College of Shanghai Jiaotong University;Shanghai 201900;P.R.China
..............page:419-422
Expression of KLF4 and Survivin protein and their relationship with clinical characteristics of esophageal carcinoma
ZHANG Zhi-ping1;2;WANG Zhou1;LIU Xiang-yan1;SHI Mo1;CHEN Gang1;SONG Liang1; WANG Yong-kang1 1.Provincial Hospital Affiliated to Shandong University;Jinan 250021;P.R.China 2.Department of Thoracic Surgery;Jinan Central Hospital;Jinan 250013;P.R.China
ZHANG Zhi-ping1;2;WANG Zhou1;LIU Xiang-yan1;SHI Mo1;CHEN Gang1;SONG Liang1; WANG Yong-kang1 1.Provincial Hospital Affiliated to Shandong University;Jinan 250021;P.R.China 2.Department of Thoracic Surgery;Jinan Central Hospital;Jinan 250013;P.R.China
..............page:406-409
Protection effect of MnTBAP on acute radiation-induced lung injury in rats
DIAO Yao1;DANG Jun2;LIU Xin-ning1;GUAN Wen-zheng3;CHE Yu-hu4;ZHAO Wen-jin1;LIU Jie1; ZHAO Xun1;YU Cheng-guo1 1.Center of Experiment and Technology;China Medical University;Shenyang 110001;P.R.China 2.Department of Radiation Oncology;First Affiliated Hospital;China Medical University;Shenyang 110001; P.R.China 3.No.94 English Class;Seven-Year System;Clinical Medicine;China Medical University;Shenyang 110001; P.R.China 4.Department of Respiratory Medicine;Liaoning Province People’s Hospital;Shenyang 110016;P.R.China
DIAO Yao1;DANG Jun2;LIU Xin-ning1;GUAN Wen-zheng3;CHE Yu-hu4;ZHAO Wen-jin1;LIU Jie1; ZHAO Xun1;YU Cheng-guo1 1.Center of Experiment and Technology;China Medical University;Shenyang 110001;P.R.China 2.Department of Radiation Oncology;First Affiliated Hospital;China Medical University;Shenyang 110001; P.R.China 3.No.94 English Class;Seven-Year System;Clinical Medicine;China Medical University;Shenyang 110001; P.R.China 4.Department of Respiratory Medicine;Liaoning Province People’s Hospital;Shenyang 110016;P.R.China
..............page:432-435
Combined chemotherapy of taxotere and cisplatin in the treatment of relapsed small cell lung cancer
QIU Bo Zhuzhou No.1 Hospital;Zhuzhou 412000;P.R.China
QIU Bo Zhuzhou No.1 Hospital;Zhuzhou 412000;P.R.China
..............page:467-468
suo la fei ni zhi liao shen ai shen yi zhi shu hou fei zhuan yi yi li bao gao
qi yuan ling yu guo hua gao jian feng
qi yuan ling yu guo hua gao jian feng
..............page:469-470
Progress on single nucleotide polymorphism and small cell lung cancer
YANG Hui-zhen;LI Rong;GAO Zhi-qiang;HAN Bao-hui Departments of Pulmonary Medicine;Affiliated Shanghai Chest Hospital;Shanghai Jiaotong University;Shanghai 200030;P.R.China
YANG Hui-zhen;LI Rong;GAO Zhi-qiang;HAN Bao-hui Departments of Pulmonary Medicine;Affiliated Shanghai Chest Hospital;Shanghai Jiaotong University;Shanghai 200030;P.R.China
..............page:475-480
Rh-endostatin combination with gecitabine as first line treatment in the elderly advanced NSCLC
CHEN Qun;SHI Qin;XIAO Song;XIE Qiang Department of Oncology;Fuzhou Pulmonary Hospital;Teaching Hospital of Fujian Medical University;Fuzhou 350008;P.R.China
CHEN Qun;SHI Qin;XIAO Song;XIE Qiang Department of Oncology;Fuzhou Pulmonary Hospital;Teaching Hospital of Fujian Medical University;Fuzhou 350008;P.R.China
..............page:461-464
Apoptosis mechanism of Lentinus edodes C91-3 apoptosis protein 24414 on human lung cancer cell line A549
LIU Ben;ZHONG Min-tao;WANG Xiao-li;SUN Wen-chang;LI Xing-yun;LIU Lei;ZHANG Wei;HUANG Min Department of Microbiology;Dalian Medical University;Dalian 116044;P.R.China
LIU Ben;ZHONG Min-tao;WANG Xiao-li;SUN Wen-chang;LI Xing-yun;LIU Lei;ZHANG Wei;HUANG Min Department of Microbiology;Dalian Medical University;Dalian 116044;P.R.China
..............page:428-431
Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancer by amplification refractory mutation system
WENG Jie1;FENG Jing-tao2;WEN Fang1;HU Jian-bing1;HU Chun-hong2 1.Department of Oncology;Yueyang First People’s Hospital;Yueyang 414000;P.R.China 2.Department of Oncology;Second Xiangya Hospital of Central South University;Changsha 410011;P.R.China
WENG Jie1;FENG Jing-tao2;WEN Fang1;HU Jian-bing1;HU Chun-hong2 1.Department of Oncology;Yueyang First People’s Hospital;Yueyang 414000;P.R.China 2.Department of Oncology;Second Xiangya Hospital of Central South University;Changsha 410011;P.R.China
..............page:440-442
Targeting therapy of lung cancer using functional monoclonal antibody 40E11
ZHANG Xiao-yan1;SUN Li-xin2;RONG Yan1;RAN Yu-liang2;YANG Zhi-hua1;SUN Li-chao1 1.Department of Gynecologic Oncology;Guangxi Cancer Hospital;Guangxi Medical University;Nanning 530021;P.R.China 2.State Key Laboratory of Molecular Oncology;Institute of Oncology;Chinese Academy of Medical Science and Peking Union Medical College;Beijing 100021;P.R.China
ZHANG Xiao-yan1;SUN Li-xin2;RONG Yan1;RAN Yu-liang2;YANG Zhi-hua1;SUN Li-chao1 1.Department of Gynecologic Oncology;Guangxi Cancer Hospital;Guangxi Medical University;Nanning 530021;P.R.China 2.State Key Laboratory of Molecular Oncology;Institute of Oncology;Chinese Academy of Medical Science and Peking Union Medical College;Beijing 100021;P.R.China
..............page:401-405,439
Randomized clinical study comparing pemetrexed plus cisplatin with gemcitabine plus cisplatin as first-line treatment in patients with advanced non-small cell lung cancer
YANG Xin-jie;ZHANG Hui;ZHANG Quan;WANG Jing-hui;NONG Jing-ying;ZHANG Shu-cai Department of Medical Oncology;Beijing Chest Hospital;Capital Medical University;Beijing 101149;P.R.China
YANG Xin-jie;ZHANG Hui;ZHANG Quan;WANG Jing-hui;NONG Jing-ying;ZHANG Shu-cai Department of Medical Oncology;Beijing Chest Hospital;Capital Medical University;Beijing 101149;P.R.China
..............page:453-456